Real-world experience with 5-aminolevulinic acid for photodynamic diagnosis of bladder cancer (2nd report): Reduced bladder recurrence after PDD-TURBT.
Hideo Fukuhara: Department of Urology, Kochi Medical School, Kohasu, Oko, Nankoku, Kochi 783-8505, Japan; Center for Photodynamic Medicine, Kochi Medical School, Kohasu, Oko, Nankoku, Kochi 783-8505, Japan. Electronic address: jm-fukuhara@kochi-u.ac.jp.
Shinkuro Yamamoto: Department of Urology, Kochi Medical School, Kohasu, Oko, Nankoku, Kochi 783-8505, Japan.
Hung Wei Lai: Center for Photodynamic Medicine, Kochi Medical School, Kohasu, Oko, Nankoku, Kochi 783-8505, Japan.
Takashi Karashima: Department of Urology, Kochi Medical School, Kohasu, Oko, Nankoku, Kochi 783-8505, Japan.
Atsushi Kurabayashi: Department of Pathology, Kochi Medical School, Kohasu, Oko, Nankoku, Kochi 783-8505, Japan.
Mutsuo Furihata: Department of Pathology, Kochi Medical School, Kohasu, Oko, Nankoku, Kochi 783-8505, Japan.
Keiji Inoue: Department of Urology, Kochi Medical School, Kohasu, Oko, Nankoku, Kochi 783-8505, Japan; Center for Photodynamic Medicine, Kochi Medical School, Kohasu, Oko, Nankoku, Kochi 783-8505, Japan.
BACKGROUND: Photodynamic diagnosis (PDD) with administration of oral aminolevulinic acid (ALA) prior to transurethral resection of bladder tumor (TURBT) can now be used for non-muscle invasive bladder cancer (NMIBC) in clinical settings in Japan. Since ALA was first marketed, a limited number of reports have described PDD-TURBT outcomes, and the effects of resecting false-positive tissue on outcomes have not been clarified. METHODS: This study compared tumor recurrence among NMIBCpatients who underwent TURBT under either white light cystoscopy (WL) or PDD. In addition, the frequency of recurrence was compared between patients with or without false-positive lesions at the time of PDD-TURBT. RESULTS: The frequency of recurrence in NMIBCpatients (cumulative number of recurrences/cumulative number of follow-up days, number of recurrences/10,000 days), including progression to muscle-invasive bladder cancer (MIBC), was 12.80 in the WL-TURBT group and 5.82 in the PDD-TURBT group (p < 0.05). tumor recurrence after TURBT was seen in 29 of 88 patients (33.0%) in the WL-TURBT group and 21 of 105 patients (20.0%) in the PDD-TURBT group (p < 0.05). Mean (± standard deviation) time to first recurrence was 249 ± 140 days in the WL-TURBT group and 419 ± 219 days in the PDD-TURBT group (p < 0.05). The frequency of recurrence in PDD-TURBT-group NMIBCpatients was significantly lower in patients with resection of false-positive tissue (4.19/10,000 days) than in those without (9.00/10,000 days, p < 0.05). CONCLUSION: The frequency of recurrence was lower and the time to recurrence was longer in the PDD-TURBT group than in the WL-TURBT group. The frequency of recurrence decreased with resection of false-positive resection.
